GNNSF (Genscript Biotech) Other Stockholders Equity: $155.9 Mil (As of Dec. 2025)


GNNSF Genscript Biotech Corp GNNSF
68 GF Score
Price $1.50
GF Value $2.81
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech Other Stockholders Equity?

Genscript Biotech GNNSF 68 Other Stockholders Equity is $155.9 Mil as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 68/100 and a GF Value™ of $2.81 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Genscript Biotech's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $155.9 Mil.

Genscript Biotech's quarterly Other Stockholders Equity increased from Dec. 2024 ($-6.8 Mil) to Jun. 2025 ($109.4 Mil) and increased from Jun. 2025 ($109.4 Mil) to Dec. 2025 ($155.9 Mil).

Genscript Biotech's annual Other Stockholders Equity declined from Dec. 2023 ($70.7 Mil) to Dec. 2024 ($-6.8 Mil) but then increased from Dec. 2024 ($-6.8 Mil) to Dec. 2025 ($155.9 Mil).

Genscript Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Genscript Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genscript Biotech Other Stockholders Equity Chart

Genscript Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.57 63.36 70.66 -6.77 155.93

Genscript Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.66 33.07 -6.77 109.38 155.93
GNNSF
68GF Score
Genscript Biotech Corp GNNSF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genscript Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $155.9 Mil mean?
Genscript Biotech (GNNSF) has a Other Stockholders Equity of $155.9 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Genscript Biotech and its competitors.
Is Genscript Biotech's Other Stockholders Equity too high?
Genscript Biotech's current Other Stockholders Equity is $155.9 Mil. Overall, Genscript Biotech has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Other Stockholders Equity compare to VRTX and REGN?
Genscript Biotech's Other Stockholders Equity of $155.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Other Stockholders Equity is $155.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.81, compared to a current price of $1.50 — trading 46.6% below its estimated fair value. The current Other Stockholders Equity is $155.9 Mil. Genscript Biotech's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Other Stockholders Equity is $155.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $1.50 is trading 46.6% below its estimated GF Value™ of $2.81. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for GNNSF:

  • Other Stockholders Equity: $155.9 Mil
  • GF Value™: $2.81 vs. price of $1.50 (46.6% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Other Exchanges 01548:Hong KongG51:Germany
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
68GF Score

Get the complete analysis for GNNSF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.50
Price
$2.81
GF Value